METTL16 and Patent ductus arteriosus: A research conducted by Lu L et al. highlights METTL16 as a significant new target for immunotherapy in pancreatic ductal adenocarcinoma (PDA), owing to its unique expression profiles across various driver gene mutations and its association with favorable prognostic outcomes.